WO1995025793A1 - Lapin transgenique sensibilise aux dyslipoproteinemies - Google Patents
Lapin transgenique sensibilise aux dyslipoproteinemies Download PDFInfo
- Publication number
- WO1995025793A1 WO1995025793A1 PCT/FR1995/000318 FR9500318W WO9525793A1 WO 1995025793 A1 WO1995025793 A1 WO 1995025793A1 FR 9500318 W FR9500318 W FR 9500318W WO 9525793 A1 WO9525793 A1 WO 9525793A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- transgenic
- rabbit
- apolipoprotein
- dna sequence
- genomic dna
- Prior art date
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 82
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 44
- 208000032928 Dyslipidaemia Diseases 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000002452 interceptive effect Effects 0.000 claims abstract description 9
- 230000007170 pathology Effects 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 102000007592 Apolipoproteins Human genes 0.000 claims description 13
- 108010071619 Apolipoproteins Proteins 0.000 claims description 13
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 12
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 2
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 1
- 238000010171 animal model Methods 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 48
- 235000012000 cholesterol Nutrition 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 108010010234 HDL Lipoproteins Proteins 0.000 description 13
- 102000015779 HDL Lipoproteins Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000012634 fragment Substances 0.000 description 10
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 102000000853 LDL receptors Human genes 0.000 description 7
- 108010001831 LDL receptors Proteins 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 101150037123 APOE gene Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 5
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 5
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 101150102415 Apob gene Proteins 0.000 description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 3
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001840 cholesterol esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 206010042573 Superovulation Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000051062 human APOA1 Human genes 0.000 description 2
- 230000003516 hyperlipidaemic effect Effects 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102100027909 Folliculin Human genes 0.000 description 1
- 101710182803 Folliculin Proteins 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 1
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 102100037814 Vigilin Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108010092427 high density lipoprotein binding protein Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000030683 polygenic disease Diseases 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Definitions
- the subject of the present invention is a transgenic rabbit expressing a protein capable of interfering in pathologies linked to dystipoproteinemias, its preparation process and its use as an animal model.
- Dyslipoproteinemias are disorders of the metabolism of lipoproteins, responsible for the transport in the blood and peripheral fluids of lipids such as cholesterol and triglycerides. They lead to significant pathologies, linked respectively to hypercolesterolemia, hypocholesterolemia or hypertriglyceridemia such as atherosclerosis in particular.
- Atherosclerosis is a complex, polygenic disease which is defined, histologically, by deposits (lipid plaques or fibro-lipid) of lipids and other blood derivatives in the wall of the large arteries (aorta, coronary arteries, carotid artery. These plaques, more or less calcified depending on the progress of the process, can be combined with lesions and are linked the accumulation in the arteries of fatty deposits consisting essentially of cholesterol esters. These plaques are accompanied by a thickening of the arterial wall, with enlargement of the smooth muscle, appearance of foam cells and accumulation of fibrous tissue.
- Atheromatous is very clearly in relief on the wall, which gives it a stenosing character r responsible for vascular occlusions by atheroma, thrombosis or embolism which occur in the most affected patients.
- Hypercholesterolaemia can therefore lead to very serious cardiovascular pathologies such as infarction, sudden death, cardiac decompensation, cerebrovascular accidents, etc.
- ⁇ is therefore particularly important to be able to quickly have treatments making it possible to decrease, in certain pathological situations, plasma cholesterol levels or even to stimulate the efflux of cholesterol (reverse transport of cholesterol) in peripheral tissues in order to discharge the cells having accumulated cholesterol against the background of the formation of an athero plaque e.
- LDL low density lipoproteins
- HDL high density lipoproteins
- an animal model capable of expressing a protein capable of interfering in pathologies linked to dyslipoproteinemias.
- Such an animal model would be particularly advantageous for the understanding of these pathologies and more particularly of the regulatory mechanisms they initiate. It would make it possible to test, in vivo and quickly, a large number of therapeutic agents to detect potential activity in terms of the expression of said proteins.
- Such a model would also be interesting for developing new therapeutic methods for the treatment of this type of pathologies such as methods based on gene therapy for example.
- the object of the present invention is precisely to propose a rabbit genetically modified in this sense.
- murins namely mice, rats and guinea pigs
- mice namely mice, rats and guinea pigs
- these small mammals are not always compatible with the intended application. This is why they are not always representative of the human model and its metabolisms.
- the chimpanzee is a control animal which is mainly used to detect therapeutic agents and vaccines directed against AIDS and cancer.
- its very high cost constitutes a major and binding handicap in terms of its use.
- the rabbit has been found in the context of the present invention, the appropriate animal model.
- the metabolism and pathologies linked to lipoproteins are known, in rabbits, exhaustively. It is an animal which is classified as "LDL mammal", that is to say that LDL are the main transporters of plasma cholesterol as in humans, unlike rats and mice which are animals classified as "mammal to HDL ".
- the present invention relates to a transgenic rabbit into the genome of which is inserted at least one exogenous genomic DNA sequence coding for a protein capable of interfering in the pathologies linked to dyslipoproteinemias.
- a transgenic rabbit according to the invention can integrate the genomic DNA sequence into all of its cells or only into a certain percentage of cells, it will then be called mosaic.
- the genomic DNA sequence is integrated at the level of all cells.
- protein capable of interfering in pathologies linked to dyslipoproteinemias is intended to cover, under the designation "apolipoproteins and any protein product having an activity linked to pathologies”. cardiovascular.
- protein product designates any mutant, fragment or peptide having at least one biological property of an apolipoprotein, as well as any natural variant of the apolipoproteins.
- genomic DNA sequence is intended to denote according to the invention, genomic DNA or a hybrid construction consisting for example of a cDNA in which one or more introns are inserted.
- genomic DNA sequence inserted according to the invention codes for all or an active part of at least one protein involved in the metabolism of lipoproteins. It could be:
- apolipoprotein chosen for example from the apolipoproteins A-I, A- ⁇ , A-IV, B, C-I,
- an enzyme such as lipoprotein lipase, hepatic lipase or lecithin cholesterol acyltransferase,
- lipid transfer protein such as the cholesterol ester transfer protein and the phospholipid transfer protein
- -a receptor chosen for example from LDL receptors, chylomicrons-remnants receptors and scavenger receptors.
- This genomic DNA sequence can also comprise several genes, organized where appropriate in the form of a cluster.
- DNA sequences inserted within the meaning of the present invention there may be mentioned more particularly the genes coding for all or an active part of the apolipoproteins AI,
- Apolipoprotein AI is a protein made up of 243 amino acids, synthesized in the form of a preproprotein of 267 residues, having a molecular mass of 28,000 daltons. It is synthesized in humans specifically in the liver and the intestine and it constitutes the essential protein of HDL particles (70% of their mass in proteins). It is abundant in plasma (1.0-1.2 g / 1). Its activity best characterized biochemically is the activation of lecithin cholesterol acyl transferase (LCAT), but many other activities are attributed to it, such as in particular the stimulation of the efflux of cellular cholesterol.
- LCAT lecithin cholesterol acyl transferase
- Apolipoprotein AI plays a major role in resistance to atherosclerosis, probably linked to the reverse transport of cholesterol, since the mere expression of this apolipoprotein in transgenic mice makes it possible to reduce the surface of lipid deposits at the level of 40 aorta compared to control mice (Rubin et al. 1993 Science, vol 365 p 762). Its gene, 1863 bp long, was cloned and sequenced (Sharpe et al., Nucleic Acids Res. 12 (9) (1984) 3917).
- protein products with apolipoprotein AI type activity mention may in particular be made of the natural variants described in the prior art (table below).
- Apolipoprotein B-100 is the major protein component of very low density lipoproteins (VLDL), low density lipoproteins (LDL) and lipoprotein Lp (a). This protein is the physiological ligand of the LDL receptor, and its plasma concentration is positively correlated with the development of atherosclerosis (Brunzell et al. 1984 Arterioscerosis 4, 79-93). ApoB-100 is one of the largest proteins known with a mass of 550 kDa and it contains 4536 amino acids (Chen et al. 1986 J; biol, Chem, 261, 12919-21). This apolipoprotein is only synthesized in the liver. Its plasma concentration is 1.0-1.2 g / l.
- ApoB-100 is the major plasma transporter of cholesterol synthesized in the liver to other cells in the body.
- Another version of apoB, apoB-48 is present in chylomicrons. In humans, apoB-48 is synthesized in the intestine. ApoB-48 has a mass of 260kDa and contains 2152 amino acids which correspond linearly to 48% on the N-terminal side of apoB-100 (Powell et al, 1987, Cell 50, 831-40). Knowing that the C-terminal half of apoB-100 contains the binding zone of apoB-100 to the LDL receptor, apoB-48 does not bind to the latter and behaves metabolically differently.
- Apolipoprotein AIV is a protein made up of 376 amino acids, synthesized specifically in the intestine in the form of a precursor of 396 residue.
- the plasma protein is relatively abundant (0.16 g / 1) and has a molecular mass of 46,000 daltons. It is a major component of the chylomicrons secreted in the lymph, but it has the distinction of being mainly in a form not associated with lipoproteins in the plasma (RB Weinberg et al., 1983, J. Lipid. Research, 24: 52- 59).
- plasma apoAIV is polymorphic, although the nature of this polymorphism is still unknown (G. Utermann et al., 1982, J. Biol. Chem.
- Apolipoprotein E comprises 317 residues, 18 of which correspond to the signal peptide. There is no propeptide.
- the apoE gene has been cloned and sequenced (approximately 3600bp) and codes for an mRNA of 1163bp, [Das et al, J. Biol. Chem., 1985, 260, 6240-6247).
- ApoE is distributed in plasma between VLDL and HDL particles. It represents around 10-20% of the VLDL proteins and 2% of the HDL proteins.
- HDL-E is a separate subclass of HDL.
- the plasma concentration of apoE is approximately 0.05 g / 1.
- ApoE is synthesized as a sialoprotein which is then desialilated in the plasma.
- apoE The synthesis of apoE is carried out by the liver and weakly by the intestine. However, unlike other apolipoproteins, apoE is also synthesized in many other tissues (brain, kidney, adrenal, reticuloendothelial cells ). ApoE recognizes with a very strong affinity the LDL receptor (apoB / E receptor) but also another receptor on liver cells which does not recognize apoB (chylomicron / remnant receptor). A polymorphism has been demonstrated on the basis of different electrophoretic mobilities. Six major phenotypes (E2 / 2, E2 / 3, E2 / 4, E3 / 4, E3 / 3, E4 / 4) have thus been described.
- the e2 allele corresponds to dyslipoproteinemia type HI (phenotype E2 / 2), a disease associated with an increase in cholesterol and triglycerides, xanthomas and early atherosclerosis.
- dyslipoproteinemia type HI phenotype E2 / 2
- An association between the e4 allele and familial Alzheimer's disease has been reported recently (Strittmatter et al. PNAS 99 (1993) 1977). More recently, the destruction of the apoE gene in mice has shown the appearance of hypersusceptibility to atherosclerosis (E. Rubin et al. Cell 1992).
- the inserted genomic DNA sequence also includes sequences allowing its expression in the cell containing it. These may be sequences which are naturally responsible for the expression of said gene when these sequences are capable of functioning in said cell. It can also be sequences of different origin (responsible for the expression of other proteins, or even synthetic). In particular, they may be sequences of eukaryotic or viral genes. By way of example, they may be promoter sequences originating from the genome of the cell which it is desired to infect, or from the genome of a virus, and in particular, the promoters of the E1A, MLP genes of adenovirus, CMV promoter, LTR-RSV, etc.
- the non-viral promoter sequences preferentially used are the ApoAI promoters or the hepatic ApoE or intestinal enhancers of the apo CIIL.
- these expression sequences can also be modified by adding activation, regulatory sequences. , etc.
- Genomic DNA can also be included in a large capacity expression vector such as the PI vectors or even the YACs.
- the present invention also relates to the protection of a transgenic rabbit according to the invention capable of interfering in pathologies related to dyslipoproteinemias.
- the invention also relates to a process for obtaining the claimed transgenic rabbit. More specifically, it relates to a process for obtaining the transgenic rabbit according to the invention using the injection into a rabbit embryo of at least one exogenous genomic DNA sequence coding for a protein capable of interfering in pathologies linked to dyslipoproteinemias, the transfer from the embryo to a recipient rabbit and after birth, the control of the presence of said genomic DNA sequence in the genome of the newborn rabbit.
- the process for obtaining according to the invention is described in more detail in Example 2 presented below. The implementation of such a method poses no difficulty to those skilled in the art familiar with micro-injection techniques, removal and implantation of embryos.
- the present invention also relates to the use of the claimed transgenic rabbit to detect the activity of therapeutic agents or therapeutic methods with a view to preventing and / or treating pathologies linked to dyslipoproteinemias as well as to methods of detecting new compounds using this rabbit and the compounds thus characterized.
- the present invention thus offers a particularly advantageous animal model for detecting therapeutic agents specific to the treatment and / or prevention of pathologies linked to dyslipoproteinemias. in particular in the field of cardiovascular diseases such as myocardial infarction, angina, sudden death, cardiac decompensation, cerebrovascular accidents. or in the field of neurological conditions where certain apolipoproteins such as apoE seem to play an important role (diseases of neuronal aging. Familial Alzheimer's, neuronal regeneration).
- FIG. 1 Representation of genomic DNA coding for apolipoprotein AI.
- Clone K 3-5-10 was isolated in this screen and analyzed against the published restriction maps for the AI / CH / AIV genomic complex (S.K. Karathanasis et al, Proc.
- the phage K3-5-10 was amplified in solid medium and its DNA prepared by conventional techniques.
- the EcoRI-BamHI restriction fragment (BamHI digestion makes it possible to separate this fragment well on an agarose gel) containing the ApoAI gene was then purified from a preparative agarose gel and dialyzed against a solution 10 mM tris pH 7-5 EDTA 0.1 nM before injection.
- the superovulation of 28 5 month old New Zealand rabbits was induced by injection of 0.375 g of FSH (folliculin stimulating hormone) from pork morning and evening for 1 day, then from 0.782 mg of FSH from pork morning and evening next day and finally 0.375 mg of pork FSH on the 3rd day in the morning.
- FSH folliculin stimulating hormone
- the 16 rabbits, in a state of superovulation were put in the presence of males of the same breed, to be fertilized.
- 0.33 mg of LH (luteising hormone) is injected into each rabbit.
- the females were separated from the males, then sacrificed. The embryos are removed by washing the uterus of each rabbit.
- the eggs still agglutinated by follicular tissue, are soaked for 20 minutes, approximately in a solution of hyaluronidase. Then they are washed twice in the Brinster's solution. To manipulate them then under the microscope, the eggs were placed in a drop of Brinster-Hepes solution added with cytochalasin. This solution allows the egg to have better resistance to injection.
- L DNA is at a concentration of 2.5 pg / ml in 10 mM Tris pH 7.5-0.1 mM EDTA.
- the 41 rabbits were analyzed as follows: The DNA, extracted from a tail fragment taken from each rabbit, is analyzed by PCR for the presence of human genomic DNA coding for ApoAI.
- the following primers, 5'-TGGCTTTCTCGCCAAGTGTCTTCAGGTGG-3 'and 5'-GACAGCGGCAGAGACTATGTGTCCCAGTTTGAA-3', are specific for the sequence of human ApAI and can amplify an 800 bp fragment in transgenic animals.
- Fresh blood samples from transgenic rabbits, 5 months old, and control rabbits were obtained by ear sampling after an overnight fast, and introduced into tubes containing ethylenediaminetetraacetic acid at final concentration of 1.5 g 1.
- the concentration of human apolipoprotein AI was quantified by the HYDRAGEL APOAIB kit (SEBIA, ref. No. 4050), agarose gels kit containing 2 antibodies monospecific polyclonal: anti apoA-I and anti apoB. These antibodies are made in rabbits, which excludes cross-reactivity between humans and rabbits.
- the total cholesterol, triglyceride and HDL (high density lipoprotein) cholesterol assays were carried out with commercial kits (Boehringer Mannheim, Germany).
- the different lipoprotein fractions were separated by ultracentrifugation according to the method of Havel et al. (RJ. Havel, H.A. Eder and J.H. Bragon, 1955, J. Clin. Invest, vol 34, 1345).
- HDL-C concentrations were approximately 2 times higher in transgenic rabbits compared to controls throughout the experiment ( Figure 3).
- a transgenic male rabbit for human and heterozygous WHHL apoA-I was then crossed with WHHL females.
- the rabbits from this cross are half heterozygous WHHL and the other half homozygous WHHL. These rabbits differ in their plasma total cholesterol levels, between 100 and 300 mg / DL for the first group and between 400 and 800 mg / Dl for the second group.
- WHHL heterozygotes and WHHL homozygotes were obtained 14 rabbits from this cross, several of which have the human apoA-I transgene, and this in the two groups of rabbits.
- transgenic rabbits expressing human apoA-I in a homozygous WHHL genetic background Using successive crosses, we therefore obtained transgenic rabbits expressing human apoA-I in a homozygous WHHL genetic background.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95913204A EP0751993A1 (fr) | 1994-03-21 | 1995-03-16 | Lapin transgenique sensibilise aux dyslipoproteinemies |
JP7524423A JPH10501683A (ja) | 1994-03-21 | 1995-03-16 | 異常リポタンパク質血症に対して感作された形質転換ウサギ |
US08/704,582 US5792902A (en) | 1994-03-21 | 1995-03-16 | Dyslipoproteinaemia-sensitized transgenic rabbit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/03263 | 1994-03-21 | ||
FR9403263A FR2718329B1 (fr) | 1994-03-21 | 1994-03-21 | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995025793A1 true WO1995025793A1 (fr) | 1995-09-28 |
Family
ID=9461240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/000318 WO1995025793A1 (fr) | 1994-03-21 | 1995-03-16 | Lapin transgenique sensibilise aux dyslipoproteinemies |
Country Status (6)
Country | Link |
---|---|
US (1) | US5792902A (fr) |
EP (1) | EP0751993A1 (fr) |
JP (1) | JPH10501683A (fr) |
CA (1) | CA2184202A1 (fr) |
FR (1) | FR2718329B1 (fr) |
WO (1) | WO1995025793A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017434A2 (fr) * | 1995-11-09 | 1997-05-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose |
WO1997021833A1 (fr) * | 1995-12-13 | 1997-06-19 | Smithkline Beecham Plc | Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques |
FR2755699A1 (fr) * | 1996-11-08 | 1998-05-15 | Rhone Poulenc Rorer Sa | Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes |
EP1049767A1 (fr) * | 1998-01-08 | 2000-11-08 | Aventis Pharmaceuticals Products Inc. | Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL356887A1 (en) | 2000-01-12 | 2004-07-12 | Yale University | Nogo receptor-mediated blockade of axonal growth |
EP1122314A1 (fr) * | 2000-02-04 | 2001-08-08 | Leja Research B.V. | Procédé de production de protéine |
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
EP1838296B1 (fr) * | 2004-10-20 | 2012-08-08 | Resverlogix Corp. | Flavanoides et isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires |
WO2007016525A2 (fr) * | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables |
ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
CA3146333A1 (fr) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires |
ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
RS58911B1 (sr) | 2011-11-01 | 2019-08-30 | Resverlogix Corp | Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone |
WO2014080291A2 (fr) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Dérivés biaryle servant d'inhibiteurs de bromodomaines |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
CA2977308A1 (fr) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions et procedes therapeutiques pour le traitement de maladies associees au complement |
EP4281034A1 (fr) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibiteurs d?utilisations cosmétiques et thérapeutiques d?atp synthase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019166A1 (fr) * | 1992-03-23 | 1993-09-30 | The University Of North Carolina At Chapel Hill | Petits animaux modeles pour l'etude de metabolisme du cholesterol |
-
1994
- 1994-03-21 FR FR9403263A patent/FR2718329B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-16 JP JP7524423A patent/JPH10501683A/ja not_active Ceased
- 1995-03-16 US US08/704,582 patent/US5792902A/en not_active Expired - Fee Related
- 1995-03-16 EP EP95913204A patent/EP0751993A1/fr not_active Withdrawn
- 1995-03-16 CA CA002184202A patent/CA2184202A1/fr not_active Abandoned
- 1995-03-16 WO PCT/FR1995/000318 patent/WO1995025793A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019166A1 (fr) * | 1992-03-23 | 1993-09-30 | The University Of North Carolina At Chapel Hill | Petits animaux modeles pour l'etude de metabolisme du cholesterol |
Non-Patent Citations (6)
Title |
---|
BIOLOGICAL ABSTRACTS, vol. 96, no. 3, 1 August 1993, Philadelphia, PA, US; abstract no. 28308, PEREVOZCHIKOV, A.P. ET AL.: "Human APO A-1 cDNA gene expression in transgenic rabbits: modeling of the neurological syndrome of human Tangier disease" page 507-508; * |
CHOWDHURY, J.R.: "Long term inprovement after ex vivo", SCIENCE, vol. 254, 20 December 1991 (1991-12-20), LANCASTER, PA US, pages 1802 * |
DUVERGER, N. ET AL.: "Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 201, no. 2, October 1991 (1991-10-01), pages 373 - 383 * |
LATTA, M. ET AL.: "Human apolipoprotein AII can be overproduced as a recombinant protein from E. coli.", CIRCULATION, vol. 86, no. 4, October 1992 (1992-10-01), pages 133 * |
MOL. BIOL., vol. 27, no. 1, 1993, MOSCOU, RUSSIE, pages 24 - 37 * |
SCHULTZ, J.R. ET AL.: "Protein composition determines the anti-atherogenic properties of HDL in transgenic mice", NATURE., vol. 365, no. 6448, 1993, LONDON GB, pages 762 - 764 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017434A2 (fr) * | 1995-11-09 | 1997-05-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose |
WO1997017434A3 (fr) * | 1995-11-09 | 1997-06-19 | Us Gov Health & Human Serv | Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose |
US6635614B1 (en) | 1995-11-09 | 2003-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol |
WO1997021833A1 (fr) * | 1995-12-13 | 1997-06-19 | Smithkline Beecham Plc | Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques |
FR2755699A1 (fr) * | 1996-11-08 | 1998-05-15 | Rhone Poulenc Rorer Sa | Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes |
WO1998021349A1 (fr) * | 1996-11-08 | 1998-05-22 | Rhone-Poulenc Rorer S.A. | Nouvelles constructions et vecteurs pour l'expression ciblee et inductible de genes |
EP1049767A1 (fr) * | 1998-01-08 | 2000-11-08 | Aventis Pharmaceuticals Products Inc. | Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle |
EP1049767A4 (fr) * | 1998-01-08 | 2002-05-08 | Aventis Pharm Prod Inc | Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle |
Also Published As
Publication number | Publication date |
---|---|
EP0751993A1 (fr) | 1997-01-08 |
CA2184202A1 (fr) | 1995-09-28 |
US5792902A (en) | 1998-08-11 |
FR2718329B1 (fr) | 2002-09-20 |
FR2718329A1 (fr) | 1995-10-13 |
JPH10501683A (ja) | 1998-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995025793A1 (fr) | Lapin transgenique sensibilise aux dyslipoproteinemies | |
Fan et al. | Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine | |
Langner et al. | The fatty liver dystrophy (fld) mutation: a new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities | |
Xu et al. | Human Apolipoprotein E2, E3, and E4 Isoform-Specific Transgenic Mice: Human-like Pattern of GlialandNeuronal Immunoreactivity in Central Nervous System Not Observed in Wild-Type Mice | |
AU720830B2 (en) | Transgenic "knock out" mice expressing a human apolipoprotein_E | |
EP0701450B1 (fr) | Virus recombinants et leur utilisation en therapie genique | |
Fan et al. | Cholesterol-fed and transgenic rabbit models for the study of atherosclerosis | |
Bosze et al. | Application of rabbits in biomedical research: a review | |
JP2002507898A (ja) | アポリポ蛋白質eトランスジェニック動物および解析方法 | |
US7960606B2 (en) | Mouse model of chronic heart failure and coronary atherosclerosis regression | |
Swanson et al. | High level expression of human apolipoprotein AI in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein AI | |
US6437215B1 (en) | SR-BI and ApoE knockout animals and use thereof as models for atherosclerosis and heart attack | |
Chan et al. | Animal models of diet-induced Hypercholesterolemia | |
US20060230466A1 (en) | Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof | |
Ge et al. | Amyloidosis in transgenic mice expressing murine amyloidogenic apolipoprotein A-II (Apoa2c) | |
Grimes et al. | Rpl3l gene deletion in mice reduces heart weight over time | |
US20190289835A1 (en) | Mouse Models Having a Knockin Scavenger Receptor Class B Type I | |
Fan et al. | Transgenic rabbits expressing human apolipoprotein (a) | |
EP2555611B1 (fr) | Préparation de protéine plasmatique de transfert des phospholipides (pltp) humaine recombinante a partir du lait d'animaux transgéniques | |
Benlian | Genetics of dyslipidemia | |
US9708609B2 (en) | Methods to screen compounds for regulating USF1 activity and methods and compounds to treat cardiometabolic and lipid pathologies | |
MXPA97001660A (en) | Method of using a dead cell receiver in the treatment of the atherosclero | |
Shimano et al. | Metabolism of chylomicron remnants in transgenic mice expressing apolipoprotein E in the intestine | |
Zhang | An animal model of atherosclerosis: The apolipoprotein E deficient mice | |
Fan et al. | Transgenic Rabbits: A Novel Model for the Study of Atherosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2184202 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995913204 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08704582 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995913204 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995913204 Country of ref document: EP |